Brief: Cosmo Pharmaceuticals Aligns With FDA On Methylene Blue MMX Second Phase III Study

Cosmo NV

21/01/2020 06:12

Jan 21 (Reuters) - COSMO PHARMACEUTICALS NV  COPN.S :
    * METHYLENE BLUE MMX REGULATORY UPDATE: SUBSTANTIAL
ALIGNMENT
REACHED WITH FDA ON SECOND PHASE III STUDY FEATURES - NEXT STEPS
    * NEXT STEP IS SUBMISSION OF PROTOCOL AND PLAN (EXPECTED IN
Q1
2020) FOR FINAL COMMENT BY FDA BEFORE TRIAL PLANNED IN H1 2020

Source text for Eikon:  ID:nTENvqm4ga 
Further company coverage:  COPN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))